Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells

Korean Journal of Parasitology

Volumn 52, Issue 4, 2014, Pages 439-442

  Yang, Zhaoshou ^a   Ahn, Hye Jin ^a   Nam, Ho Woo ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

EGFR tyrosine kinase; Gefitinib; Rhoptry kinase; Small molecule; Toxoplasma gondii; Toxoplasmosis; Treatment

Indexed keywords

CRIZOTINIB; GEFITINIB; SUNITINIB; ANTIPROTOZOAL AGENT; QUINAZOLINE DERIVATIVE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GROWTH INHIBITION; HELA CELL LINE; NONHUMAN; TOXOPLASMA GONDII; DOSE RESPONSE; DRUG EFFECTS; DRUG REPOSITIONING; DRUG SENSITIVITY; GROWTH, DEVELOPMENT AND AGING; HUMAN; TOXOPLASMA;

TOXOPLASMA GONDII;

ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG REPOSITIONING; HELA CELLS; HUMANS; PARASITIC SENSITIVITY TESTS; QUINAZOLINES; TOXOPLASMA;

EID: 84907149529     PISSN: 00234001     EISSN: 17380006     Source Type: Journal    
DOI: 10.3347/kjp.2014.52.4.439     Document Type: Article

References (9)

1. John DT, Petri WA (eds). The tissue coccidia: Toxoplasma gondii. Markell and Voge’s Medical Parasitology (9th ed.). Elsevier Inc., USA. 2006, p 139-149.
2. Choi WY, Nam HW, Kwak NH, Huh W, Kim YR, Kang MW, Cho SY. Foodborne outbreaks of human toxoplasmosis. J Infect Dis 1997; 175: 1280-1282.
3. Park YH, Han JH, Nam HW. Clinical features of ocular toxoplasmosis in Korean patients. Korean J Parasitol 2011; 49: 157-171.
4. Wei F, Wang W, Liu Q. Protein kinases of Toxoplasma gondii: functions and drug targets. Parasitol Res 2013; 112: 2121-2129.
5. Qui W, Wernimont A, Tang K, Taylor S, Lunin V, Schapira M, Fentress S, Hui R, Sibley LD. Novel structural and regulatory features of rhoptry secretory kinases in Toxoplasma gondii. EMBO J 2009; 28: 969-979.
6. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nature Rev (Cancer) 2009; 9: 28-39.
7. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM. EGFR ad MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and Gefitinib resistance in lung cancers. Nature Med 2012; 18: 74-82.
8. Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, McTigue M, Grodsky N, Ryan K, Padrique E, Alton G, Timofeevski S, Yamazaki S, Li Q, Zou H, Christensen J, Mroczkowski B, Bender S, Kania RS, Edwards MP. Structure based drug design of Crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011; 54: 6342-6363.
9. Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, Bray MA, Carpenter AE, Moore CB, Siddiqi N, Rubin EJ, Hung DT. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog 2014; 10: 1-16.